Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

Post by: Diane De wyngaert in Immunic Press Release
NEW YORK, Nov. 18, 2021…
read more
22 Nov 2021
0

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

Post by: Diane De wyngaert in Immunic Press Release
– Fully Enrolled Phase 2…
read more
04 Nov 2021
0

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

Post by: Diane De wyngaert in Minoryx Press Release
Presentation highlights reduction in cerebral…
read more
03 Nov 2021
0

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Post by: Diane De wyngaert in Novadip Press Release
Novadip Biosciences announces EUR 19…
read more
28 Oct 2021
0

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

Post by: Diane De wyngaert in Immunic Press Release
  – Top-Line Data Expected…
read more
28 Oct 2021
0